ArticleNature communications2017
Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 102 citations in OpenAlex.
- Intratumoral Sotigalimab with Pembrolizumab Induces Rapid Activation of Antigen-Presenting Cells and Drives Antitumor Responses in Non-injected Tumors in Metastatic Melanoma: A Phase I/II Study.Cancer discovery · 2026Trial
- CD40 agonism in renal cell carcinoma enhances immune checkpoint activity through myeloid cells.iScience · 2026Article
- IL1R1 blockade augments CD40 agonist mediated immunity in pancreatic cancer.Scientific reports · 2026Article
- RAS/MEK/PI3K pathway inhibition augments response to CD40 agonism by targeting CD11bNature communications · 2026Article
- Circulating IFNγ-associated protein signatures predict response to neoadjuvant immunotherapy in patients with stage III melanoma.Cancer cell international · 2025Article
- Intratumoral expression of IL-12 and CD40 ligand (CD154) from plasmids generates antitumor responses that eliminate tumoral T regs.Scientific reports · 2025Article
- Beyond monotherapy: multimodal strategies integrating immune checkpoint inhibitors in lymphoma management.Frontiers in immunology · 2025Review
- Allogeneic stem cells engineered to release interferon β and scFv-PD1 target glioblastoma and alter the tumor microenvironment.Cytotherapy · 2024Article
- The Role of CD4 T Cell Help in CD8 T Cell Differentiation and Function During Chronic Infection and Cancer.Immune network · 2023Review
- Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity.Cancer immunology research · 2023Article
- Sustained Intratumoral Administration of Agonist CD40 Antibody Overcomes Immunosuppressive Tumor Microenvironment in Pancreatic Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- A mitochondria-localized iridium(iii) photosensitizer for two-photon photodynamic immunotherapy against melanoma.Chemical science · 2023Article
- Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages.Cancer cell international · 2023Review
- Adrenergic receptor signaling regulates the CD40-receptor mediated anti-tumor immunity.Frontiers in immunology · 2023Article
- Low-density lipoprotein balances T cell metabolism and enhances response to anti-PD-1 blockade in a HCT116 spheroid model.Frontiers in oncology · 2023Article
- Cancer vaccine strategies for the treatment of diffusely infiltrating gliomas.Therapeutic advances in vaccines and immunotherapy · 2023Review
- Construction and Identification of an NLR-Associated Prognostic Signature Revealing the Heterogeneous Immune Response in Skin Cutaneous Melanoma.Clinical, cosmetic and investigational dermatology · 2023Article
- [Melanoma-associated macrophages-from molecular signals to therapeutic application].Dermatologie (Heidelberg, Germany) · 2022Review
- Nanomaterials-Mediated Co-Stimulation of Toll-Like Receptors and CD40 for Antitumor Immunity.Advanced materials (Deerfield Beach, Fla.) · 2022Article
- Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons.Cell communication and signaling : CCS · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 1 institution in 1 country.
Manisha SinghDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77054, USA.
Christina ViandenDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77054, USA.
Mark J CantwellMemgen, LLC Houston, TX, 77046, USA.
Zhimin DaiDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77054, USA.
Zhilan XiaoDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77054, USA.
Meenu SharmaDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77054, USA.
Hiep KhongDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77054, USA.ORCID http://orcid.org/0000-0003-4888-7862
Ashvin R JaiswalDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77054, USA.
Faisal FaakDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77054, USA.
Yared HailemichaelDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77054, USA.
L M E JanssenDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77054, USA.
Uddalak BharadwajDepartment of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, 77054, USA.
Michael A CurranDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77054, USA.
Adi DiabDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77054, USA.
Roland L BassettDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77054, USA.
David J TweardyDepartment of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, 77054, USA.
Patrick HwuDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77054, USA.
Willem W OverwijkDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77054, USA. WOverwijk@mdanderson.org.
The University of Texas MD Anderson Cancer Center · US
Funding
UT M.D. Anderson Cancer Center SPORE in MelanomaP50CA093459 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GRIMM, ELIZABETH A · 2004 to 2014
$23.7MNCI NIH HHS P50 CA093459
Abstract
CD40 agonists bind the CD40 molecule on antigen-presenting cells and activate them to prime tumor-specific CD8
Indexed as
AdenoviridaeAnimalsBrainBrain NeoplasmsCD40 AntigensCD40 LigandCD4-CD8 RatioCD8-Positive T-LymphocytesCell Line, TumorCTLA-4 AntigenEnzyme ActivationFemaleImmunotherapyMelanoma, ExperimentalMiceMice, Inbred C57BLCD40 AntigensCD40 LigandCTLA-4 AntigenPdcd1 protein, mouseProgrammed Cell Death 1 Receptor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.